Irritable Bowel Syndrome Clinical Trial
Official title:
"Functional Bowel Disorder. Investigation in General Practice"
The study aims to investigate how to give the diagnosis of Irritable Bowel Syndrome.
The investigators compare two parallel groups of primary care patients, in the age of 18-50
years with gastrointestinal complaints where the GP suspects IBS. All included patients
fulfil international diagnostic criteria (ROME III) and have no danger signals.
Group 1: The diagnosis is based on the diagnostic criteria and few blod tests Group 2: The
diagnosis is a diagnosis of exclusion after investigations with extended blod tests,
examination for milk- and gluten intolerance, stoll for ova and parasites and scopy of the
intestine.
After receiving the diagnosis of Irritable bowel syndrome all patients are informed about
the condition.
The investigators follow the patients for 1 year. The investigators hypothesis is that the
two investigation programmes (group 1 and 2)are equal with respect to the patients´ quality
of life, symptoms and satisfaction and also with respect to finding of organic diseases.
Background: Two opposing approaches can be distinguished in establishing the diagnosis of
Irritable Bowel Syndrome (IBS): IBS as a "diagnosis of exclusion" versus IBS as a syndromic
condition on its own. In Denmark we have no consensus on how to establish the diagnosis, but
must often GPs approach IBS as a diagnosis of exclusion. Guidelines from the United Kingdom
and the United States recommend the second approach, where the diagnosis is given as a
positive diagnosis based on symptom-based IBS criteria. We lack research on this area
carried out under controlled circumstances and in primary care in Denmark.
Aim: To evaluate two investigation programmes for diagnosing IBS in primary care patients in
Denmark. We want to compare the two programmes in relation to the effect on the patients´
symptoms, quality of life and satisfaction, and also the cost and safety when using the
different programmes. Also we want to see how the GP´s understanding of IBS correlate with
the IBS criteria (ROM I, II and III)
Methods: A randomised, non-blinded, controlled intervention study of two parallel groups.
The target group comprises people aged 18-50 years, who consult their GP with
gastrointestinal complaints, where the GP suspects IBS and refers the patient to the study.
To be included in the study the patients have to fulfil the ROM III criteria and they may
not have any alarm signals. Included patients are randomised to one of two different
investigation programmes, where the diagnosis is given as:
1. A positive diagnosis, the diagnosis is based on the ROM III criteria and a few blood
tests (FBC, CRP)
2. A diagnosis of exclusion, the diagnosis is given after normal investigation (extended
blood tests, screening for celiac sprue and lactose intolerance, endoscopy)
The patients are followed by means of monthly letters, with questions about current GI
symptoms, sick-leave days, visits at GPs, use of medication etc., and validated
questionnaires at baseline, after 4 weeks, 6 months and 12 months.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |